Kora Healthcare, an emerging Dublin-based pharma company, today announced it has acquired Chifam Inc, a Canadian-based speciality pharma company focussed on immunotherapy and immune modulation. The acquisition of Chifam Inc by Kora Healthcare is via its Canadian entity Kora Healthcare Canada Inc. No deal terms have been disclosed.
The acquisition of Chifam Inc provides Kora Healthcare with the operational infrastructure and licenses for greater expansion of its pharma portfolio in Canada and North America. Prior to the acquisition, Chifam had been a long-term distributor of a key drug product for Kora Healthcare in Canada. Following the acquisition, all patients and patient stakeholders can and will continue to be able to source Chifam product via existing and well-established channels.
Kora Healthcare’s acquisition of Chifam is part of its wider targeted acquisition and investment strategy in well-established life science companies and product portfolio’s within niche market segments and string underlying growth drivers.
About Kora Healthcare:
Kora Healthcare is emerging company committed to identifying, developing and commercialising healthcare products internationally across supportive care, genito-urinary medicine and consumer care. Kora Healthcare is headquartered in Dublin, Ireland with a presence in York, UK and Toronto, Canada as well as an indirect presence in over 30 countries.
Chifam Inc. is a Canadian company dedicated to specialized healthcare with a therapeutic focus on immunotherapy and immune modulation for speciality or rare diseases.
Advisers: Loopstra Nixon LLP acted as legal counsel to Kora Healthcare.
Contact Kora Healthcare:
+353 (0)1 8900406
Dublin, Ireland, October 4, 2021